Form 4: Helius Medical Technologies Director Paul Buckman Granted Stock Options

Director Paul Buckman received stock options for Helius Medical Technologies, Inc. under the 2022 Equity Incentive Plan.

Summary

• On January 6, 2025, Paul Buckman, a director of Helius Medical Technologies, Inc., was granted stock options to purchase 10,732 shares of Class A Common Stock.
• The exercise price of the options is $0.7292 per share.
• 50% of the options vested immediately, with the remaining options vesting in equal quarterly installments starting March 31, 2025, contingent upon continued service.
• The options expire on January 5, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate practice of incentivizing directors with stock options, which is generally viewed positively as it aligns interests with shareholders. The vesting schedule is also a positive sign of long-term commitment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service and contribution to the company.

Risks

• The value of the stock options is dependent on the future performance of Helius Medical Technologies, Inc.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice to incentivize and retain key personnel, aligning their interests with the company's long-term success. This is a standard compensation practice in the biotech industry.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotechnology industry.
• Companies like NeuroMetrix and Second Sight Medical Products have used similar equity-based compensation plans to attract and retain talent.
• The vesting schedule and exercise price are generally aligned with industry benchmarks for companies of similar size and stage of development.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the director to work towards increasing shareholder value.
• The director benefits from the potential future value of the stock options.

Key Dates

Keywords

stock options, director, Helius Medical Technologies, HSDT, equity incentive plan, beneficial ownership, Form 4